Weekly Funding Opportunities

[med-Research]

Medline Community Impact Grant Program<https://www.medline.com/pages/community-impact-grant/>
Throughout our nation we are faced with many health inequities. Health outcomes for people living in vulnerable communities, and already disproportionately impacted by social determinants of health (SDOH), are at an even greater health risk. SDOH are the economic and social conditions that influence individual and group differences in health status. Medline is committed to social determinants of health and through the Community Impact Grant Program we can promote good health for all people.­ ­
Medline is investing resources to help non-profit organizations address prevalent health challenges, stimulate health equity and improve population health in under resourced areas. We will award results-focused grants that offer community- centered solutions and immediate impact. Through collaboration with community experts, we can provide essential resources, re-direct adverse outcomes and improve the well-being of people. This is, and always will be, our ongoing commitment to communities. $25,000 awards.
Due August 27, 2021. Med-RA deadline to receive draft documents: August 16.

Program on the Origins of Gastroesophageal Cancers (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-026.html>
The National Cancer Institute (NCI) is publishing this Funding Opportunity Announcement (FOA) to request applications for the Program on the Origins of Gastroesophageal Cancers (R01). This new program will build on recent molecular classifications of gastroesophageal cancers, significant understanding of their cancer genomics, and advances in stem cell research to examine and define how these related cancers initially evolve at the cellular level. The program will address the complex mechanisms and effectors that direct the proliferation and expansion of tumor-initiating cells and their progeny to initiate these cancers. The focus of the FOA is on gastric and gastroesophageal junction adenocarcinomas. The program is envisioned to provide unprecedented opportunities to outline the earliest cellular changes in transformation that precede any histological manifestations or neoplasia. This new program will be composed of up to six large R01 research grants (to be supported by this FOA) and one Coordinating Center grant (to be supported by the companion FOA, RFA-CA-21-027<https://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-027.html>).
Due October 8, 2021. Med-RA deadline to receive draft documents: September 27.

CCRP Initiative: Chemical Threat Agent-induced Pulmonary and Ocular Pathophysiological Mechanisms (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-ES-21-006.html>
The purpose of this Funding Opportunity Announcement (FOA) is to support research seeking to understand mechanisms of chemical toxicity and to identify potential molecular/genetic targets that reduce acute effects of chemical threat agents that affect the lungs and eyes. These discoveries can lead to exploration of therapeutic countermeasures through early stage development efforts supported by the Countermeasures Against Chemical Threats (CounterACT) NIH-wide program, a component within the Chemical Countermeasures Research Program (CCRP).
Due October 13, 2021; September 21, 2022; and September 20, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30.

Innovative Models for Delivering PrEP and STI Services to Stop HIV in the United States (R61 / R33 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-069.html>
The purpose of this FOA is to encourage and support the development of effective strategies for expanding the provision of HIV pre-exposure prophylaxis for people at increased risk but currently lacking these services by leveraging existing sexually transmitted infection programs. Funding for the fourth and fifth years(s) will be dependent upon achieving negotiated Go/No-go criteria and milestones.
Due October 13, 2021. Med-RA deadline to receive draft documents: September 30.

HEAL Initiative: Planning Studies for Initial Analgesic Development Initial Translational Efforts [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-029.html>
The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-015.html> HEAL Initiative: Team Research – for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.
Due October 13, 2021; June 9, 2022; October 11, 2022; June 9, 2023; October 10, 2023. Med-RA deadline to receive draft documents for October 13, 2021 due date: September 30.

Exploratory Studies to Investigate the Mechanisms of Interrelationship between Sleep and Substance Use Disorders (R61/R33)
R61/R33 Basic Experimental Studies with Humans Required<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-029.html>
The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs.
R61/R33 Clinical Trials Not Allowed<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-016.html>
The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics.
Due October 14, 2021. Med-RA deadline to receive draft documents: October 4.

Exploratory Studies to Investigate the Mechanisms of Interrelationship Between Sleep and Substance Use Disorders (R61/R33)
Clinical Trials Not Allowed<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-016.html>
Basic Experimental Studies with Humans Required<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-029.html>
The purpose of this FOA is to support research project applications that are developmental and exploratory in nature to expand our knowledge on the basic neurobiology of the interrelationship between sleep and substance use disorders (SUDs). These mechanistic studies will not only offer an insight into the fundamental processes that link substance use disorders to disorders of sleep regulation and vice-versa but may also have implications for managing the risk for the development of SUDs and identifying new targets for prevention and therapeutics. Projects may explore the molecular, cellular, circuit and behavioral interactions between sleep and SUDs.
Due October 14, 2021. Med-RA deadline to receive draft documents: October 4.

Promoting a Basic Understanding of Chemical Threats to Skin (R34 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/pa-files/PAS-21-245.html>
This Funding Opportunity Announcement (FOA) is to support applications to a new NIAMS initiative to encourage the skin research community to contribute to basic understanding of skin injuries caused by chemical threats to the civilian population, with an emphasis on investigating the commonalities of such injuries and identifying potential shared signaling pathways and therapeutic targets for countermeasure development.
Standard dates apply. Expires September 8, 2024. Med-RA deadline to receive draft documents for October 16, 2021 standard date: October 5.

NIDCD Research Grants for Translating Basic Research into Clinical Tools (R01- Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DC-22-001.html>
This Funding Opportunity Announcement (FOA) is intended to provide an avenue for basic scientists, clinicians and clinical scientists to jointly initiate and conduct translational research projects which translate basic research findings into clinical tools for better human health. The scope of this FOA includes a range of activities to encourage translation of basic research findings which will impact the diagnosis, treatment and prevention of communication disorders. Connection to the clinical condition must be clearly established and the outcomes of the grant must have practical clinical impact.
Due October 20, 2021; June 20, 2022; February 22, 2023; October 18, 2023; June 20, 2024. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.

Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 / R01 Clinical Trial Required)
R34<https://grants.nih.gov/grants/guide/pa-files/PAR-21-240.html>
The goal of this funding opportunity is to support early phase clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high priority research topics. This funding opportunity is intended to support feasibility clinical trials, which will provide data that are critical for the planning and design of a subsequent clinical efficacy or effectiveness study, or a pragmatic trial. The data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of interventions lacking published data; adapting an intervention to a specific population; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention and data collection procedures; refining and assessing the feasibility of protocolized multimodal interventions; or examining acceptability and adherence of control conditions. This FOA will not support randomized clinical trials that test or determine efficacy or effectiveness; nor will this FOA support repetition of feasibility or acceptability research that has been previously conducted in the same or similar patient population with the same or similar intervention. Applications that propose solely to write a protocol or manual of operations or to develop infrastructure for a clinical trial are not appropriate for this announcement. Applications must propose to conduct a feasibility clinical trial. The subsequent larger trial should have the potential to make a significant impact on public health.
R01<https://grants.nih.gov/grants/guide/pa-files/PAR-21-241.html>
This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health
Due October 20, 2021; February 18, 2022; June 20, 2022; October 19, 2022; February 21, 2023; June 20, 2023; October 20, 2023; February 20, 2024. Med-RA deadline to receive draft documents for October 20, 2021 due date: October 7.

Promoting Bunyavirales Basic Science Research (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-21-046.html>
The purpose of this Funding Opportunity Announcement (FOA) is to stimulate fundamental research of human disease-causing pathogens in the Bunyavirales order by supporting projects studying vector competence, virology, pathogenesis, and immunity.
Due October 22, 2021. Med-RA deadline to receive draft documents: October 11.

High Resolution Mapping of Biomolecules in Brain Cells in Aging and Alzheimer’s Disease (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-019.html>
This Funding Opportunity Announcement (FOA) will use the R01 funding mechanism to support discrete, specified, and circumscribed projects on novel molecular imaging approaches to establish high-resolution mapping of biomolecules in brain cells and regions during the course of aging and Alzheimer’s disease (AD).
Due October 28, 2021. Med-RA deadline to receive draft documents: October 18.

Leveraging Existing Large Databases and Cohorts to Better Understand the Risks and Benefits of Long-Term Osteoporosis Therapy and Drug Holiday (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-018.html>
This Funding Opportunity Announcement (FOA) solicits secondary analyses of existing datasets to provide evidence about appropriate strategies for long-term osteoporosis therapies, including drug holidays, and to better understand their risks and benefits. This FOA encourages interdisciplinary studies utilizing innovative analytical approaches such as modeling studies or causal inference methods using data sources from large cohort studies, healthcare systems including the Veterans Administration (VA), Centers for Medicare and Medicaid Services (CMS), FDA Sentinel network, Agency for Healthcare Research and Quality (AHRQ), Centers for Disease Control and Prevention (CDC), and other public, private, or commercial datasets. The generalizability of study results is critical, and datasets should be representative of the population receiving osteoporosis therapy. Identification of disparities in outcomes according to demographic, ethnic, clinical, social, and other factors are particularly encouraged.
Due October 28, 2021. Med-RA deadline to receive draft documents: October 18.

Role of Adaptive Immunity in Etiology of Alzheimer’s Disease and Alzheimer’s Disease-Related Dementias (R01 Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-AG-22-017.html>
This Funding Opportunity Announcement (FOA) aims to explore the role of adaptive immunity in Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). Specifically, the FOA seeks an understanding of brain immune surveillance, the generation of CNS-directed immune responses in neurodegenerative disorders, and the functional role of adaptive immunity in AD/ADRD onset and progression.
Due October 28, 2021. Med-RA deadline to receive draft documents: October 18.

BRAIN Initiative: Optimization of Transformative Technologies for Large Scale Recording and Modulation in the Nervous System (U01 Clinical Trials Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-027.html>
Understanding the dynamic activity of neural circuits is central to the NIH BRAIN Initiative. The invention, proof-of-concept investigation, and optimization of new technologies through iterative feedback from end users are key components of the BRAIN Initiative. This FOA seeks applications to optimize existing or emerging technologies through iterative testing with end users. The technologies and approaches should have potential to address major challenges associated with recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). These technologies and approaches should have previously demonstrated their transformative potential through initial proof-of-concept testing and are now ready for accelerated refinement. In conjunction, the manufacturing techniques should be scalable towards sustainable, broad dissemination and user-friendly incorporation into regular neuroscience research.
Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, electrical, magnetic, acoustic or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.
Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023. Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18.

BRAIN Initiative: New Technologies and Novel Approaches for Recording and Modulation in the Nervous System (R01 Clinical Trial Not Allowed)<https://grants.nih.gov/grants/guide/rfa-files/RFA-NS-21-026.html>
Understanding the dynamic activity of brain circuits is central to the NIH BRAIN Initiative. This FOA seeks applications for proof-of-concept testing and development of new technologies and novel approaches for recording and modulation (including various modalities for stimulation/activation, inhibition and manipulation) of cells (i.e., neuronal and non-neuronal) and networks to enable transformative understanding of dynamic signaling in the central nervous system (CNS). This FOA seeks exceptionally creative approaches to address major challenges associated with recording and modulating CNS activity, at or near cellular resolution, at multiple spatial and/or temporal scales, in any region and throughout the entire depth of the brain. It is expected that the proposed research may be high-risk, but if successful, could profoundly change the course of neuroscience research.
Proposed technologies should be compatible with experiments in behaving animals, validated under in vivo experimental conditions, and capable of reducing major barriers to conducting neurobiological experiments and making new discoveries about the CNS. Technologies may engage diverse types of signaling beyond neuronal electrical activity such as optical, magnetic, acoustic and/or genetic recording/manipulation. Applications that seek to integrate multiple approaches are encouraged. If suitable, applications are expected to integrate appropriate domains of expertise, including biological, chemical and physical sciences, engineering, computational modeling and statistical analysis.
Due October 29, 2021; May 2, 2022; October 28, 2022; May 1, 2023; October 27, 2023. Med-RA deadline to receive draft documents for October 29, 2021 due date: October 18.

Prevention of Perinatal Depression: Improving Intervention Delivery for At-Risk Individuals (R34 / R01 Clinical Trial Required)
R34<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-241.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-21-240.html>
The purpose of these Funding Opportunity Announcements (FOAs) is to encourage research addressing major gaps identified in the United States Preventive Services Task Force recommendation statement concerning interventions to prevent perinatal depression, with an emphasis on populations experiencing mental health disparities. The research scope for these FOAs includes: 1) refining and pilot testing strategies for identifying women at risk for perinatal depression; 2) developing and testing tools for selecting those most likely to benefit from preventive interventions; 3) refining and testing service-ready efficacious preventive interventions that are of appropriate intensity/dose, and are scalable, such that they can be delivered with fidelity by setting providers; and, 4) optimizing and testing strategies that can be used to train providers and to support delivery of evidence-based approaches with fidelity across diverse health care and community settings.
Due November 9, 2021. Med-RA deadline to receive draft documents: October 27.

PrEP for HIV Prevention among Substance Using Populations (R01 – Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-017.html>
NIDA is interested in research that addresses research gaps related to PrEP and its use among people who use drugs (PWUD), with the goals of improving PrEP uptake, adherence and implementation. Current US Public Health Service PrEP guidelines recommend PrEP for people who inject drugs (PWID) and mention alcohol and illicit drug use as potential concerns for clinical management. More systematic data are needed regarding the impact of substance use on PrEP management and adherence, as well as the best ways to deliver PrEP and integrate it with other services. Recent trials have demonstrated the efficacy of injectable Cabotegravir as PrEP, although no data exist for PWUD and there is a need to inform the best practices for delivery and management of injectable PrEP among PWUD, as well as for oral PrEP. This RFA is restricted to projects conducted in the United States. Applications are encouraged that propose research in states and counties identified in the US Government’s Ending the HIV Epidemic (EHE) initiative. Applications to work in locales that are not included in the EHE initiative must provide an epidemiologic justification for their inclusion in the research.
Due November 12, 2021. Med-RA deadline to receive draft documents: November 1.

Organoid Modeling of Neural Stimulants and HIV Comorbidity of Human Brain (R01- Clinical Trial Optional)<https://grants.nih.gov/grants/guide/rfa-files/RFA-DA-22-009.html>
This Funding Opportunity Announcement (FOA) invites grant applications to study mechanisms underlying the neuropathophysiology of HIV-associated neurological disorders (HAND) using induced microglia and cerebral organoids generated from human derived induced pluripotent stem cell (iPSC) lines. Specific emphasis is on the comorbidity of HIV and neural stimulants, including methamphetamine, amphetamine, cocaine, and nicotine, studied at the single cell and neural circuits levels.
Due November 17, 2021. Med-RA deadline to receive draft documents: November 3.

Understanding Oral Human Papillomavirus (HPV) Infection, Acquisition, and Persistence in People Living with HIV (R21 / R01 Clinical Trial Not Allowed)
R21<https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-004.html>
R01<https://grants.nih.gov/grants/guide/rfa-files/RFA-DE-22-003.html>
The purpose of these Funding Opportunity Announcements is to solicit research to better understand the epidemiology and biology of oral human papillomavirus (HPV) infection, its acquisition and persistence, in people living with HIV and elucidate the initial mechanisms related to HPV-associated oral and oropharyngeal cancers and warts in the context of HIV. The FOAs intend to address broad knowledge gaps related to biological, immunogenetic, clinical, and socio-behavioral factors and mechanisms for oral HPV co-infection and persistence in the oral cavity and oropharynx of HIV-seropositive individuals.
Due November 18, 2021. Med-RA deadline to receive draft documents: November 4.

To search for additional funding opportunities, please visit CoM’s unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20210714/658d080a/attachment.html>